Challenges in modelling the Charcot-Marie-Tooth neuropathies for therapy development

Manisha Juneja, Joshua Burns, Mario da Cunha Saporta, Vincent Timmerman

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Much has been achieved in terms of understanding the complex clinical and genetic heterogeneity of Charcot-Marie-Tooth neuropathy (CMT). Since the identification of mutations in the first CMT associated gene, PMP22, the technological advancement in molecular genetics and gene technology has allowed scientists to generate diverse animal models expressing monogenetic mutations that closely resemble the CMT phenotype. Additionally, one can now culture patient-derived neurons in a dish using cellular reprogramming and differentiation techniques. Nevertheless, despite the fact that finding a disease-causing mutation offers a precise diagnosis, there is no cure for CMT at present. This review will shed light on the exciting advancement in CMT disease modelling, the breakthroughs, pitfalls, current challenges for scientists and key considerations to move the field forward towards successful therapies.

Original languageEnglish (US)
Pages (from-to)58-67
Number of pages10
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume90
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Tooth
Mutation
Charcot-Marie-Tooth Disease
Genetic Heterogeneity
Therapeutics
Genes
Molecular Biology
Animal Models
Technology
Phenotype
Neurons

Keywords

  • HMSN (CHARCOT-MARIE-TOOTH)
  • neuropathy

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Challenges in modelling the Charcot-Marie-Tooth neuropathies for therapy development. / Juneja, Manisha; Burns, Joshua; da Cunha Saporta, Mario; Timmerman, Vincent.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 90, No. 1, 01.01.2019, p. 58-67.

Research output: Contribution to journalArticle

@article{33a85de44409454884057847a2d3c088,
title = "Challenges in modelling the Charcot-Marie-Tooth neuropathies for therapy development",
abstract = "Much has been achieved in terms of understanding the complex clinical and genetic heterogeneity of Charcot-Marie-Tooth neuropathy (CMT). Since the identification of mutations in the first CMT associated gene, PMP22, the technological advancement in molecular genetics and gene technology has allowed scientists to generate diverse animal models expressing monogenetic mutations that closely resemble the CMT phenotype. Additionally, one can now culture patient-derived neurons in a dish using cellular reprogramming and differentiation techniques. Nevertheless, despite the fact that finding a disease-causing mutation offers a precise diagnosis, there is no cure for CMT at present. This review will shed light on the exciting advancement in CMT disease modelling, the breakthroughs, pitfalls, current challenges for scientists and key considerations to move the field forward towards successful therapies.",
keywords = "HMSN (CHARCOT-MARIE-TOOTH), neuropathy",
author = "Manisha Juneja and Joshua Burns and {da Cunha Saporta}, Mario and Vincent Timmerman",
year = "2019",
month = "1",
day = "1",
doi = "10.1136/jnnp-2018-318834",
language = "English (US)",
volume = "90",
pages = "58--67",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Challenges in modelling the Charcot-Marie-Tooth neuropathies for therapy development

AU - Juneja, Manisha

AU - Burns, Joshua

AU - da Cunha Saporta, Mario

AU - Timmerman, Vincent

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Much has been achieved in terms of understanding the complex clinical and genetic heterogeneity of Charcot-Marie-Tooth neuropathy (CMT). Since the identification of mutations in the first CMT associated gene, PMP22, the technological advancement in molecular genetics and gene technology has allowed scientists to generate diverse animal models expressing monogenetic mutations that closely resemble the CMT phenotype. Additionally, one can now culture patient-derived neurons in a dish using cellular reprogramming and differentiation techniques. Nevertheless, despite the fact that finding a disease-causing mutation offers a precise diagnosis, there is no cure for CMT at present. This review will shed light on the exciting advancement in CMT disease modelling, the breakthroughs, pitfalls, current challenges for scientists and key considerations to move the field forward towards successful therapies.

AB - Much has been achieved in terms of understanding the complex clinical and genetic heterogeneity of Charcot-Marie-Tooth neuropathy (CMT). Since the identification of mutations in the first CMT associated gene, PMP22, the technological advancement in molecular genetics and gene technology has allowed scientists to generate diverse animal models expressing monogenetic mutations that closely resemble the CMT phenotype. Additionally, one can now culture patient-derived neurons in a dish using cellular reprogramming and differentiation techniques. Nevertheless, despite the fact that finding a disease-causing mutation offers a precise diagnosis, there is no cure for CMT at present. This review will shed light on the exciting advancement in CMT disease modelling, the breakthroughs, pitfalls, current challenges for scientists and key considerations to move the field forward towards successful therapies.

KW - HMSN (CHARCOT-MARIE-TOOTH)

KW - neuropathy

UR - http://www.scopus.com/inward/record.url?scp=85050134239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050134239&partnerID=8YFLogxK

U2 - 10.1136/jnnp-2018-318834

DO - 10.1136/jnnp-2018-318834

M3 - Article

VL - 90

SP - 58

EP - 67

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 1

ER -